Citius Pharmaceuticals is trading at $0.37, down 6.42%, with no fresh company-specific announcement identified to explain the October 22 move.
- The latest identified company release was an October 12 investor-conference announcement.
- Broader markets were under pressure amid geopolitical tensions and risk-off sentiment, which may have contributed, but no direct link to the stock’s decline was established. Healthcare was comparatively stronger, with XLV up 1.35%, so sector weakness does not explain the drop.